Page last updated: 2024-11-13
cep-9722
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CEP-9722: a prodrug of the poly(ADP-ribose) polymerase inhibitor CEP-8983 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 24780387 |
| CHEMBL ID | 4297461 |
| SCHEMBL ID | 3359996 |
| MeSH ID | M000605228 |
Synonyms (17)
| Synonym |
|---|
| SCHEMBL3359996 |
| cep 9722 [who-dd] |
| 1h-cyclopenta(a)pyrrolo(3,4-c)carbazole-1,3(2h)-dione, 4,5,6,7-tetrahydro-11-methoxy-2-((4-methyl-1-piperazinyl)methyl)- |
| b68083e4yg , |
| unii-b68083e4yg |
| 916574-83-9 |
| 4,5,6,7-tetrahydro-11-methoxy-2-((4-methyl-1-piperazinyl)methyl)-1h-cyclopenta(a)pyrrolo(3,4-c)carbazole-1,3(2h)-dione |
| cep-9722 |
| cep 9722 |
| 11-methoxy-2-((4-methylpiperazin-1-yl)methyl)-4,5,6,7-tetrahydro-1h-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2h)-dione |
| DB14882 |
| CHEMBL4297461 |
| nsc768593 |
| nsc-768593 |
| HY-105303 |
| 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione |
| CS-0025682 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Grade 3/4 hematologic adverse events included neutropenia (28%) and leukopenia (11%); adverse events led to discontinuation in 33% of patients." | ( An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors. Aftimos, P; Awada, A; Bahleda, R; Bourbouloux, E; Campone, M; Frenel, JS; Gombos, A; Soria, JC; Varga, A, 2016) | 0.66 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " The primary objective of this study was to determine the maximum-tolerated dose of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors." | ( An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors. Aftimos, P; Awada, A; Bahleda, R; Bourbouloux, E; Campone, M; Frenel, JS; Gombos, A; Soria, JC; Varga, A, 2016) | 0.88 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.83
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.83) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||